The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease

Jerry R. Colca, Philipp E. Scherer

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations

Abstract

Background: Chronic disease appears connected to obesity. However, evidence suggests that chronic metabolic diseases are more specifically related to adipose dysfunction rather than to body weight itself. Scope of review: Further study of the first generation “insulin sensitizer” pioglitazone and molecules based on its structure suggests that is possible to decouple body weight from the metabolic dysfunction that drives adverse outcomes. The growing understanding of the mechanism of action of these agents together with advances in the pathophysiology of chronic metabolic disease offers a new approach to treat chronic conditions, such as type 2 diabetes, fatty liver disease, and their common organ and vascular sequelae. Major conclusions: We hypothesize that treating adipocyte dysfunction with new insulin sensitizers might significantly impact the interface of infectious disease and chronic metabolic disease.

Original languageEnglish (US)
Article number101409
JournalMolecular Metabolism
Volume55
DOIs
StatePublished - Jan 2022

Keywords

  • COVID-19
  • Insulin sensitizers
  • Metabolic syndrome
  • Mitochondrial pyruvate carrier
  • NAFLD
  • TZDs

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Fingerprint

Dive into the research topics of 'The metabolic syndrome, thiazolidinediones, and implications for intersection of chronic and inflammatory disease'. Together they form a unique fingerprint.

Cite this